Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis

Immunological Reviews

Volumn 233, Issue 1, 2010, Pages 233-255

  Bartok, Beatrix ^a   Firestein, Gary S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokines; Inflammation; Rheumatoid arthritis; Signaling protein

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AGGRECANASE; ARRY 162; BIOLOGICAL MARKER; BIRB 794; CASPASE; CATHEPSIN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; FAS ANTIGEN; FOSTAMINIB; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; MATRIX METALLOPROTEINASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PAMAPIMOD; PROTEIN BCL 2; PROTEIN KINASE SYK INHIBITOR; PROTEIN P53; PROTEINASE; SCIO 469; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VX 702;

ADAPTIVE IMMUNITY; ANGIOGENESIS; APOPTOSIS; B LYMPHOCYTE; CARTILAGE; CARTILAGE DEGENERATION; CELL DEATH; CELL SURVIVAL; CELL TYPE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE EXACERBATION; EFFECTOR CELL; EXTRACELLULAR MATRIX; FIBROBLAST LIKE SYNOVIOCYTE; GENE EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; JOINT DESTRUCTION; MACROPHAGE; NONHUMAN; ONCOGENE; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SYNOVIOCYTE; SYNOVIUM; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ADAPTIVE IMMUNITY; ANIMALS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; CYTOKINES; FIBROBLASTS; HUMANS; HYPERPLASIA; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; PHENOTYPE; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 73249125200     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2009.00859.x     Document Type: Review

References (142)

1. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009 11 : 229.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003 423 : 356 361.
3. Bresnihan B, Flanagan AM. Synovium. In : Firestein GS, Budd RC, Harris T, McInnes IB, Ruddy S, Sergent JS eds. Kelly's Textbook of Rheumatology. 8th edn. Philadelphia, PA : Saunders Elsevier, 2009 : 23 37.
4. Edwards JC, Willoughby DA. Demonstration of bone marrow derived cells in synovial lining by means of giant intracellular granules as genetic markers. Ann Rheum Dis 1982 41 : 177 182.
5. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996 39 : 1781 1790.
6. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In : Firestein GS, Budd RC, Harris T, McInnes IB, Ruddy S, Sergent JS eds. Kelly's Textbook of Rheumatology. 8th edn. Philadelphia, PA : Saunders Elsevier, 2009 : 1035 1086.
7. Valencia X, et al. Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med 2004 200 : 1673 1679.
8. Lee DM, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007 315 : 1006 10010.
9. Szekanecz Z, et al. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994 3 : 221 231.
10. Morales-Ducret J, Wayner E, Elices MJ, Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol 1992 149 : 1424 1431.
11. Takemura S, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001 167 : 1072 1080.
12. Pap T, Gay S. Fibroblasts and fibroblast-like synoviocytes. In : Firestein GS, Budd RC, Harris T, McInnes IB, Ruddy S, Sergent JS eds. Kelly's Textbook of Rheumatology. 8th edn. Philadelphia, PA : Saunders Elsevier, 2009 : 201 214.
13. Marinova-Mutafchieva L, Williams RO, Funa K, Maini RN, Zvaifler NJ. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 2002 46 : 507 513.
14. Nakajima T, et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 1995 38 : 485 491.
15. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995 96 : 1631 1638.
16. Matsumoto S, Müller-Ladner U, Gay RE, Nishioka K, Gay S. Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. J Rheumatol 1996 23 : 1345 1352.
17. Perlman H, Georganas C, Pagliari LJ, Koch AE, Haines K 3rd., Pope RM. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. J Immunol 2000 164 : 5227 5235.
18. Kammouni W, Wong K, Ma G, Firestein GS, Gibson SB, El-Gabalawy HS. Regulation of apoptosis in fibroblast-like synoviocytes by the hypoxia-induced Bcl-2 family member Bcl-2/adenovirus E1B 19-kd protein-interacting protein 3. Arthritis Rheum 2007 56 : 2854 2863.
19. Imamura F, et al. Monoclonal expansion of synoviocytes in rheumatoid arthritis. Arthritis Rheum 1998 41 : 1979 1986.
20. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998 28 : 197 208.
21. Franz JK, et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum 2000 43 : 599 607.
22. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2000 2 : 59 64.
23. Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL, Zvaifler NJ. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996 149 : 2143 2151.
24. Tak PP, et al. p53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. Arthritis Rheum 1999 42 : 948 953.
25. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997 94 : 10895 10900.
26. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002 99 : 10025 10030.
27. Han Z, Boyle DL, Shi Y, Green DR, Firestein GS. Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum 1999 42 : 1088 1092.
28. Lee SH, et al. Microsatellite instability and suppressed DNA repair enzyme expression in rheumatoid arthritis. J Immunol 2003 170 : 2214 2220.
29. Rosengren S, Boyle DL, Firestein GS. Acquisition, culture, and phenotyping of synovial fibroblasts. Methods Mol Med 2007 135 : 365 375.
30. Kiener HP, Brenner MB. Building the synovium: cadherin-11 mediates fibroblast-like synoviocyte cell-to-cell adhesion. Arthritis Res Ther 2005 7 : 49 54.
31. Kiener HP, Lee DM, Agarwal SK, Brenner MB. Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro. Am J Pathol 2006 168 : 1486 1499.
32. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 1989 83 : 1267 1276.
33. Müller-Ladner U, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996 149 : 1607 1615.
34. Fassbender HG, Simmling-Annefeld M. The potential aggressiveness of synovial tissue in rheumatoid arthritis. J Pathol 1983 139 : 399 406.
35. Pierer M, Müller-Ladner U, Pap T, Neidhart M, Gay RE, Gay S. The SCID mouse model: novel therapeutic targets - lessons from gene transfer. Springer Semin Immunopathol 2003 25 : 65 78.
36. Pap T, et al. Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2004 50 : 2794 2802.
37. Müller-Ladner U, et al. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. Arthritis Rheum 1999 42 : 490 497.
38. Müller-Ladner U, et al. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. J Immunol 1997 158 : 3492 3498.
39. Rème T, Travaglio A, Gueydon E, Adla L, Jorgensen C, Sany J. Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue. Clin Exp Immunol 1998 111 : 353 358.
40. Inazuka M, et al. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology (Oxford) 2000 39 : 262 266.
41. Aupperle KR, et al. Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J Pathol 1998 152 : 1091 1098.
42. Pap T, Aupperle KR, Gay S, Firestein GS, Gay RE. Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis Rheum 2001 44 : 676 681.
43. Simelyte E, Rosengren S, Boyle DL, Corr M, Green DR, Firestein GS. Regulation of arthritis by p53: critical role of adaptive immunity. Arthritis Rheum 2005 52 : 1876 1884.
44. Yamanishi Y, et al. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 2002 160 : 123 130.
45. Tak PP, Klapwijk MS, Broersen SF, van de Geest DA, Overbeek M, Firestein GS. Apoptosis and p53 expression in rat adjuvant arthritis. Arthritis Res 2000 2 : 229 235.
46. Roivainen A, Jalava J, Pirilä L, Yli-Jama T, Tiusanen H, Toivanen P. H-ras oncogene point mutations in arthritic synovium. Arthritis Rheum 1997 40 : 1636 1643.
47. Cannons JL, Karsh J, Birnboim HC, Goldstein R. HPRT- mutant T cells in the peripheral blood and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 1998 41 : 1772 1782.
48. Da Sylva TR, Connor A, Mburu Y, Keystone E, Wu GE. Somatic mutations in the mitochondria of rheumatoid arthritis synoviocytes. Arthritis Res Ther 2005 7 : R844 R851.
49. Yamanishi Y, et al. p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis. Arthritis Res Ther 2005 7 : R12 R18.
50. Simelyte E, Boyle DL, Firestein GS. DNA mismatch repair enzyme expression in synovial tissue. Ann Rheum Dis 2004 63 : 1695 1699.
51. Jascur T, Boland CR. Structure and function of the components of the human DNA mismatch repair system. Int J Cancer 2006 119 : 2030 2035.
52. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 1989 109 : 877 889.
53. Müller-Ladner U, et al. Alternatively spliced CS-1 fibronectin isoform and its receptor VLA-4 in rheumatoid arthritis synovium. J Rheumatol 1997 24 : 1873 1880.
54. Kiener HP, Niederreiter B, Lee DM, Jimenez-Boj E, Smolen JS, Brenner MB. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis Rheum 2009 60 : 1305 1310.
55. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998 161 : 409 414.
56. Asahara H, et al. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum 1997 40 : 912 918.
57. Shiozawa S, Shimizu K, Tanaka K, Hino K. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest 1997 99 : 1210 1216.
58. Aikawa Y, et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol 2008 26 : 817 823.
59. Han Z, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001 108 : 73 81.
60. Inoue T, Hammaker D, Boyle DL, Firestein GS. Regulation of JNK by MKK-7 in fibroblast-like synoviocytes. Arthritis Rheum 2006 54 : 2127 2135.
61. Yoshizawa T, Hammaker D, Sweeney SE, Boyle DL, Firestein GS. Synoviocyte innate immune responses: I. differential regulation of interferon responses and the JNK pathway by MAPK kinases. J Immunol 2008 181 : 3252 3258.
62. Sweeney SE, Hammaker D, Boyle DL, Firestein GS. Regulation of c-Jun phosphorylation by the I kappa B kinase-epsilon complex in fibroblast-like synoviocytes. J Immunol 2005 174 : 6424 6430.
63. Sweeney SE, Mo L, Firestein GS. Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3. Arthritis Rheum 2007 56 : 743 752.
64. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005 52 : 2656 2665.
65. Makkonen KM, Pasonen-Seppänen S, Törrönen K, Tammi MI, Carlberg C. Regulation of the hyaluronan synthase 2 gene by convergence in cyclic AMP response element-binding protein and retinoid acid receptor signaling. J Biol Chem 2009 284 : 18270 18281.
66. Boyle DL, Sajjadi FG, Firestein GS. Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 1996 39 : 923 930.
67. Yamanishi Y, et al. Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol 2002 168 : 1405 1412.
68. Stanton H, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005 434 : 648 652.
69. Korb A, Pavenstädt H, Pap T. Cell death in rheumatoid arthritis. Apoptosis 2009 14 : 447 454.
70. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005 4 : 139 163.
71. Kurowska M, et al. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J Immunol 2002 169 : 1760 1767.
72. Liu H, et al. Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. J Immunol 2005 175 : 8337 8345.
73. Okamoto K, et al. Fas-associated death domain protein is a Fas-mediated apoptosis modulator in synoviocytes. Rheumatology (Oxford) 2000 39 : 471 480.
74. Mountz JD, Zhang HG. Regulation of apoptosis of synovial fibroblasts. Curr Dir Autoimmun 2001 3 : 216 239.
75. Pierer M, et al. The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis. Rheumatology (Oxford) 2007 46 : 1063 1070.
76. Hayashi S, et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 2007 56 : 1067 1075.
77. Meyer LH, Franssen L, Pap T. The role of mesenchymal cells in the pathophysiology of inflammatory arthritis. Best Pract Res Clin Rheumatol 2006 20 : 969 981.
78. Ichikawa K, et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003 171 : 1061 1069.
79. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005 280 : 15709 15718.
80. Audo R, Combe B, Coulet B, Morel J, Hahne M. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases. Cell Death 2009 16 : 1227 1237.
81. Bai S, et al. NF-kappaB-regulated expression of cellular FLIP protects rheumatoid arthritis synovial fibroblasts from tumor necrosis factor alpha-mediated apoptosis. Arthritis Rheum 2004 50 : 3844 3855.
82. Palao G, et al. Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis Rheum 2006 54 : 1473 1481.
83. Meinecke I, et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc Natl Acad Sci USA 2007 104 : 5073 5078.
84. Cha HS, Rosengren S, Boyle DL, Firestein GS. PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes. Arthritis Rheum 2006 54 : 587 592.
85. You X, Boyle DL, Hammaker D, Firestein GS. PUMA-mediated apoptosis in fibroblast-like synoviocytes does not require p53. Arthritis Res Ther 2006 8 : R157.
86. Lindhout E, van Eijk M, van Pel M, Lindeman J, Dinant HJ, de Groot C. Fibroblast-like synoviocytes from rheumatoid arthritis patients have intrinsic properties of follicular dendritic cells. J Immunol 1999 162 : 5949 5956.
87. Hayashida K, Shimaoka Y, Ochi T, Lipsky PE. Rheumatoid arthritis synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells in a CD49/CD29-CD106-dependent mechanism. J Immunol 2000 164 : 1110 1116.
88. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 2001 107 : 305 315.
89. Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem J 2009 420 : 1 16.
90. Radstake TR, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004 50 : 3856 3865.
91. Seibl R, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003 162 : 1221 1227.
92. Brentano F, Kyburz D, Schorr O, Gay R, Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol 2005 233 : 90 96.
93. van der Heijden IM, et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000 43 : 593 598.
94. Rosengren S, Hoffman HM, Bugbee W, Boyle DL. Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis 2007 64 : 708 714.
95. Ospelt C, et al. Expression, regulation, and signaling of the pattern-recognition receptor nucleotide-binding oligomerization domain 2 in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009 60 : 355 363.
96. Patel DD, Haynes BF. Leukocyte homing to synovium. Curr Dir Autoimmun 2001 3 : 133 167.
97. Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001 98 : 39 45.
98. Nanki T, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4 + T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000 165 : 6590 6598.
99. Tsubaki T, et al. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin Exp Immunol 2005 141 : 363 371.
100. Schmutz C, et al. Chemokine receptors in the rheumatoid synovium: upregulation of CXCR5. Arthritis Res Ther 2005 7 : R217 R229.
101. Sawai H, Park YW, Roberson J, Imai T, Goronzy JJ, Weyand CM. T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. Arthritis Rheum 2005 52 : 1392 1401.
102. van der Voort R, et al. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum 2005 52 : 1381 1391.
103. Murphy G, Caplice N, Molloy M. Fractalkine in rheumatoid arthritis: a review to date. Rheumatology (Oxford) 2008 47 : 1446 1451.
104. Pierer M, et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004 172 : 1256 1265.
105. Wells TN, Power CA, Shaw JP, Proudfoot AE. Chemokine blockers - therapeutics in the making? Trends Pharmacol Sci 2006 27 : 41 47.
106. Proudfoot AE. Is CCR2 the right chemokine receptor to target in rheumatoid arthritis? Arthritis Rheum 2008 58 : 1889 1891.
107. Waldburger JM, Firestein GS. Garden of therapeutic delights: new targets in rheumatic diseases. Arthritis Res Ther 2009 11 : 206.
108. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002 6 : 357 376.
109. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008 118 : 3537 3545.
110. Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. IV. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med 1989 170 : 865 875.
111. Genovese MC, Chakravarty EF, Krishnan E, Moreland LW. A randomized, controlled trial of interferon-beta-1a in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis Res Ther 2004 6 : R73 R77.
112. Corr M, Boyle DL, Ronacher L, Flores N, Firestein GS. Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta. Ann Rheum Dis 2009 68 : 257 263.
113. Lundy SK, Sarkar S, Tesmer LA, Fox DA. Cells of the synovium in rheumatoid arthritis T lymphocytes. Arthritis Res Ther 2007 9 : 202.
114. Firestein GS, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994 37 : 644 652.
115. Kasperkovitz PV, et al. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis Rheum 2005 52 : 430 441.
116. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002 298 : 1911 1912.
117. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999 291 : 124 130.
118. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008 67 : 909 1016.
119. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008 47 : 409 414.
120. Schett G, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000 43 : 2501 2512.
121. Inoue T, et al. Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc Natl Acad Sci USA 2006 103 : 5484 5489.
122. Inoue T, Hammaker D, Boyle DL, Firestein GS. Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes. J Immunol 2005 174 : 4301 4306.
123. Yoshizawa T, et al. Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J Immunol 2009 183 : 1360 1367.
124. Köller M, et al. JNK1 is not essential for TNF-mediated joint disease. Arthritis Res Ther 2005 7 : R166 R173.
125. Sundarrajan M, Boyle DL, Chabaud-Riou M, Hammaker D, Firestein GS. Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK. Arthritis Rheum 2003 48 : 2450 2460.
126. Hammaker DR, Boyle DL, Chabaud-Riou M, Firestein GS. Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. J Immunol 2004 172 : 1612 1618.
127. Hammaker DR, Boyle DL, Inoue T, Firestein GS. Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis Res Ther 2007 9 : R57.
128. Toh ML, Yang Y, Leech M, Santos L, Morand EF. Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids. Arthritis Rheum 2004 50 : 3118 3128.
129. Svensson CI, et al. Gadd45beta deficiency in rheumatoid arthritis: enhanced synovitis through JNK signaling. Arthritis Rheum 2009 60 : 3229 3240.
130. Firestein GS. NF-kappaB: holy Grail for rheumatoid arthritis? Arthritis Rheum 2004 50 : 2381 2386.
131. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008 47 : 584 590.
132. Aupperle K, Bennett B, Han Z, Boyle D, Manning A, Firestein G. NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001 166 : 2705 2711.
133. Tak PP, et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001 44 : 1897 1907.
134. Ichikawa H, Takada Y, Murakami A, Aggarwal BB. Identification of a novel blocker of I kappa B alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kappa B-regulated gene products. J Immunol 2005 174 : 7383 7392.
135. Tas SW, et al. Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adeno-associated virus type 5. Hum Gene Ther 2006 17 : 821 832.
136. Alten RE, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 2009 doi :.
137. Cohen SB, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009 60 : 317 320.
138. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009 60 : 1232 1241.
139. Weinblatt ME, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008 58 : 3309 3318.
140. Kremer JM, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009 60 : 1895 1905.
141. Cha HS, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006 317 : 571 578.
142. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004 36 : 372 378.